- Stock Information
- News Releases
- Corporate Governance
- SEC Filings
- Annual Reports
- Financial Reports
- Event Calendar
- Non-GAAP Measures
- Information Request
- Analyst Coverage
|Covidien Announces New Data on Hernia and Abdominal Wall Repair Products to Be Presented at Hernia Repair 2011|
NORTH HAVEN, Conn., Mar 14, 2011 (BUSINESS WIRE) --
Covidien (NYSE: COV), a leading global provider of healthcare products, announced that new data on its hernia and abdominal wall repair products will be presented at Hernia Repair 2011, the 14th Annual Meeting & Scientific Program of the American Hernia Society. Covidien products will be featured in two podium presentations and nine poster sessions, as well as Company-sponsored symposia.
Highlights include results from multicenter studies demonstrating that Covidien products have the potential to play an increasingly important role in reducing postoperative pain and complications in open and laparoscopic hernia and abdominal wall repair procedures. The meeting runs from March 16 to 19 in San Francisco, CA.
Title: Open Inguinal Hernia without Fixation - Preliminary
Results of Comparative Randomized Study (Covidien-sponsored study)
AHS Non-Complex Hernia Symposium: Advancements in Hernia Repair
Title: Optimizing Outcomes in LVHR: Review of Long-Term, Human
Title: ProGrip(TM) Self-Fixating Mesh: Benefits of a Self-Gripping
Mesh - Update on the Current Efficacy and Safety
Title: Pain Management in Open Inguinal Hernia Repair: Nerve
Resection vs. ProGrip(TM) Mesh
AHS Complex Hernia Symposium: Implant Durability vs. Rapid Remodeling
Title: Managing the Complex Ventral Hernia Patient: Treatment
Considerations for a Successful Repair
Title: The Effect of Partial Crosslinking on Remodeling with a
Surgical Implant: What Does the Literature Show?
Title: Early Results from a Retrospective Study Evaluating the
Use of Permacol(TM) Biologic Implant in the Repair of Abdominal Wall
Defects. (Covidien-sponsored study).
In addition, independent surgeons will be presenting new data supporting the adoption of:
Covidien featured products include:
Parietex(TM) Optimized Composite Mesh (PCO Optimized) - 510(k) clearance pending. Designed to deliver optimal strength, optimal handling and optimal outcomes.
AbsorbaTack Fixation Device - A sterile, single-use device designed for fixation of prosthetic material, such as hernia mesh, to soft tissues in laparoscopic abdominal wall surgeries and open hernia repair. The tack is constructed of an absorbable synthetic polyester copolymer derived from lactic and glycolic acid.
Parietex ProGrip Self-fixating Mesh -- Designed for ease of use, resorbable polylactic acid (PLA) microgrips enable surgeons to position and securely place the mesh in under 60 seconds without the use of additional fixation. Tension is evenly distributed for patient comfort.
Permacol Biologic Implant -- The processing of this porcine dermal collagen implant gently removes cells, cell debris, DNA and RNA without damaging the 3D collagen matrix. The resulting acellular collagen matrix is then cross-linked for enhanced durability throughout the wound healing process in complex abdominal wall and hernia repairs.
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2010 revenue of $10.4 billion, Covidien has approximately 42,000 employees worldwide in more than 60 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.